Emergency Medicine Cases – Where the Experts Keep You in the Know. For complete episodes please visit emergencymedicinecases.com
Kurt Schalper, MD, PhD - Navigating the Complexities of Biomarker Testing in the Expanding Field of Precision Immuno-Oncology: Latest Evidence, Current Challenges, and Practical Guidance for Pathologists
Manage episode 277769400 series 103624
By PeerView Press, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.
Go online to PeerView.com/JZJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies are demonstrating remarkable clinical activity in an increasing number of malignancies, and as the immunotherapy arsenal has continued to expand, so has the importance of predictive biomarkers to guide clinical decisions and identify patients who are most likely to benefit from specific immune checkpoint inhibitors or combinations. A number of proven and putative biomarkers have been and continue to be evaluated, including PD-L1 expression, MSI/MMR, TMB, LAG-3, and others. Pathologists play an essential role in carrying out appropriate testing for these biomarkers. This onDemand activity based on a recent live PeerView Virtual Seminar and Workshop provides pathology professionals with evidence-based and practical expert instruction on biomarker testing in the era of precision cancer immunotherapy. In the Seminar segments, an expert panel reviews evidence on current and emerging immunotherapies and biomarkers, and the Workshop segments focus on the nuances of applying this evidence to pathology practice, as well as strategies for collaborating with oncology professionals to interpret biomarker testing results when making clinical decisions for patients with cancer. Upon completion of this activity, participants should be better able to: Evaluate the latest evidence on established/emerging biomarkers (including PD-L1, MSI/MMR, and TMB, among others) and the rationale for their use to predict benefit from cancer immunotherapies, Discuss practical aspects of immunotherapy biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, cutpoints, and other nuances, Apply the latest evidence and recommendations for cancer immunotherapy biomarker testing in community and academic settings, Implement effective strategies for interdisciplinary collaboration and coordination among pathologists, oncologists, and other key professionals regarding selection and interpretation of immunotherapy biomarker tests to guide clinical decision-making in immuno-oncology.